Interaction of organic cations with a newly identified plasma membrane monoamine transporter.
Many endogenous compounds and xenobiotics are organic cations that rely on polyspecific organic cation transporters (OCTs) to traverse cell membranes. We recently cloned a novel human plasma membrane monoamine transporter (PMAT) that belongs to the equillibrative nucleoside transporter (ENT) family. We have reported previously that, unlike other ENTs, PMAT (also known as ENT4) is a Na+-independent and membrane potential-sensitive transporter that transports monoamine neurotransmitters and the neurotoxin 1-methyl-4-phenylpyridinium (MPP+). These compounds are the known substrates for OCTs, which raises the possibility that PMAT functions as a polyspecific transporter like the OCTs. In the present study, we analyzed the interaction of PMAT with a series of structurally diverse organic cations using MDCK cells stably expressing human PMAT. Our study showed that PMAT interacts with many organic cations that have heterogeneous chemical structures. PMAT transports classic OCT substrates, such as tetraethylammonium, guanidine, and histamine. Prototype OCT inhibitors, including cimetidine, and type II cations (e.g., quinidine, quinine, verapamil, and rhodamine123) are also PMAT inhibitors. An analysis of molecular structures and apparent binding affinities revealed that charge and hydrophobicity are the principal determinants for transporter-substrate/inhibitor interaction. A planar aromatic mass seems to be important for high affinity interaction. trans-Stimulation and efflux studies demonstrate that PMAT is able to mediate bidirectional transport. These functional properties of PMAT are strikingly similar to those of the OCTs. We therefore conclude that PMAT can function as a polyspecific organic cation transporter, which may play a role in organic cation transport in vivo.
Engel
Karen
K
Department of Pharmaceutics, University of Washington, H272J, Health Sciences Building, Seattle, WA 98195-7610, USA.
Wang
Joanne
J
D015655:1-Methyl-4-phenylpyridinium / Q000493:pharmacokinetics; D000818:Animals; D001692:Biological Transport; D002460:Cell Line; D004285:Dogs; D033705:Equilibrative Nucleoside Transport Proteins; D006801:Humans; D026901:Membrane Transport Proteins / Q000502:physiology*; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D027701:Organic Cation Transport Proteins / Q000502:physiology*; D014439:Tyramine / Q000493:pharmacokinetics
D033705:Equilibrative Nucleoside Transport Proteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D027701:Organic Cation Transport Proteins; C495988:SLC29A4 protein, human; D015655:1-Methyl-4-phenylpyridinium; D014439:Tyramine